hotspot -WSS

hotspot

author：comprehensive 2025-09-29 16:35:01 - browse：9613

The removal of small amounts of brain tissue from desperately ill patients, done as part of a Mount Sinai research project, triggered alarm bells at the Food and Drug Administration and has raised broader questions about the scientific and ethical justification for live-brain research. Journalist and STAT contributor Katherine Eban joins “The Readout LOUD” podcast to discuss the results of a two-year investigation.

Also on this week’s episode, we discuss Novartis’ effort to acquire MorphoSys, and the latest news on Eli Lilly and Novo Nordisk’s blockbuster obesity drugs with Elaine Chen, the newest member of STAT’s biotech reporting team.

For more on what we cover, here’s STAT’s investigation into the Mount Sinai brain-tissue research project; here’s exclusive reporting on the MorphoSys drug at the center of the Novartis acquisition, and Adam Feuerstein’s take on where it might run off the rails; and here’s STAT’s reporting on Novo Nordisk and its weight loss drug Wegovy.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban
Next article： Why Medicare shouldn’t cover every FDA

knowledge

WSS

Bernie Sanders is gearing up to subpoena pharma CEOs

AstraZeneca loses challenge to Medicare drug price negotiation

FDA does about

International team creates first chimeric human

New clues to why women have higher risk of autoimmune disorders

Wegovy leads to weight loss. Can it treat depression, too?

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

knowledge

Heart attack and stroke risk calculators need revising

Covid isolation guidance eased by the CDC

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Abortion pill mifepristone to soon be dispensed at CVS, Walgreens

Bright Health sells Medicare Advantage business to Molina

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Trump demands the U.S. pay no more for drugs than other countries … again

House looks to weaken Medicare negotiation

Hollywood unions extend contract negotiations for actors

Why you shouldn’t ask, “What country has the best health care?”

explore

Scientists unlock the key to scar

Venture capital firm's plans to take over Akron hospital face hurdles

Medicare drug price negotiation legal challenge met with skepticism

Zyn nicotine pouches become unlikely player in latest culture war

FDA does about

ALS groups 'won't be played again' by the FDA, drug sponsors

hotspot

knowledge

focus

Wikipedia